New mRNA vaccines to boost T-cell therapies for solid tumors
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors
This project explores how new mRNA vaccines, like those for COVID-19, can make T-cell treatments more effective against tough cancers such as pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11132668 on NIH RePORTER |
What this research studies
We are exploring how to adapt the successful mRNA vaccine technology, similar to the COVID-19 vaccines, to fight solid tumors. These vaccines use a special modification that helps reduce side effects and increase the body's immune response. Our goal is to develop new mRNA vaccines specifically for hard-to-treat cancers like pancreatic cancer, by teaching the immune system to recognize unique markers on tumor cells. We will work to make these vaccines as effective as possible in boosting the body's own T-cells to attack cancer.
Who could benefit from this research
Good fit: This research is foundational and aims to benefit patients with solid tumors, particularly those with pancreatic cancer, who may eventually receive T-cell transfer therapies.
Not a fit: Patients whose cancers do not respond to T-cell therapies or who have other cancer types not targeted by this specific research may not directly benefit from this particular approach.
Why it matters
Potential benefit: If successful, this work could lead to more powerful and effective T-cell therapies for patients with solid tumors, offering new hope for difficult-to-treat cancers.
How similar studies have performed: While mRNA vaccines have shown remarkable success against viral infections, their application in cancer immunotherapy, especially with T-cell transfer, is a newer and actively developing area.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Radu, Caius Gabriel — University of California Los Angeles
- Study coordinator: Radu, Caius Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.